Immunomedics deal

Pharmacia retains the exclusive license to market and sell a third product, ImmuRAID-CEA, in the U.S. and Canada. ImmuRAID-CEA is under FDA review as a colorectal cancer imaging agent, and is in Phase III studies for lung cancer imaging and Phase I/II for breast cancer imaging. The FDA last month sent a not approvable letter the Morris Plains, N.J., company for ImmuRAID-CEA to treat colorectal cancer, and IMMU is awaiting a meeting with the agency to clarify the issues, which remain undisclosed.

(Separately, IMMU said a suit has been filed in the U.S. District Court for the District of New Jersey alleging disclosure violations relating to the company's ability to obtain FDA approval for ImmuRAID-CEA. The complaint seeks unspecified damages and other relief. IMMU said the suit is without merit.) ...